These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 28489856)

  • 21. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
    Slama L; Landman R; Assoumou L; Benalycherif A; Samri A; Joly V; Pialoux G; Valin N; Cabié A; Duvivier C; Lambert-Niclot S; Marcelin AG; Peytavin G; Costagliola D; Girard PM;
    J Antimicrob Chemother; 2016 Aug; 71(8):2252-61. PubMed ID: 27068399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
    Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
    Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence of virological failure and major regimen change of initial combination antiretroviral therapy in the Latin America and the Caribbean: an observational cohort study.
    Cesar C; Jenkins CA; Shepherd BE; Padgett D; Mejía F; Ribeiro SR; Cortes CP; Pape JW; Madero JS; Fink V; Sued O; McGowan C; Cahn P;
    Lancet HIV; 2015 Nov; 2(11):e492-500. PubMed ID: 26520929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful antiretroviral therapy delivery and retention in care among asymptomatic individuals with high CD4+ T-cell counts above 350 cells/μl in rural Uganda.
    Jain V; Byonanebye DM; Amanyire G; Kwarisiima D; Black D; Kabami J; Chamie G; Clark TD; Rooney JF; Charlebois ED; Kamya MR; Havlir DV;
    AIDS; 2014 Sep; 28(15):2241-9. PubMed ID: 25022596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey.
    Ávila-Ríos S; García-Morales C; Matías-Florentino M; Romero-Mora KA; Tapia-Trejo D; Quiroz-Morales VS; Reyes-Gopar H; Ji H; Sandstrom P; Casillas-Rodríguez J; Sierra-Madero J; León-Juárez EA; Valenzuela-Lara M; Magis-Rodríguez C; Uribe-Zuñiga P; Reyes-Terán G;
    Lancet HIV; 2016 Dec; 3(12):e579-e591. PubMed ID: 27658867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
    Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
    Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.
    Nadler JP; Gathe JC; Pollard RB; Richmond GJ; Liao Q; Griffith S; Lancaster CT; Hernandez JE; Pappa KA;
    BMC Infect Dis; 2003 Jun; 3():10. PubMed ID: 12795812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-infected ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/μL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea.
    Campbell JD; Moore D; Degerman R; Kaharuza F; Were W; Muramuzi E; Odongo G; Wetaka M; Mermin J; Tappero JW
    Clin Infect Dis; 2012 Apr; 54(8):1204-11. PubMed ID: 22423133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks.
    Molina JM; Podsadecki TJ; Johnson MA; Wilkin A; Domingo P; Myers R; Hairrell JM; Rode RA; King MS; Hanna GJ
    AIDS Res Hum Retroviruses; 2007 Dec; 23(12):1505-14. PubMed ID: 18160008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
    MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
    Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Morbidity before and after HAART initiation in Sub-Saharan African HIV-infected adults: a recurrent event analysis.
    Seyler C; Messou E; Gabillard D; Inwoley A; Alioum A; Anglaret X
    AIDS Res Hum Retroviruses; 2007 Nov; 23(11):1338-47. PubMed ID: 18184075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequency of Viremic Episodes in HIV-Infected Women Initiating Antiretroviral Therapy During Pregnancy: A Cohort Study.
    Myer L; Dunning L; Lesosky M; Hsiao NY; Phillips T; Petro G; Zerbe A; McIntyre JA; Abrams EJ
    Clin Infect Dis; 2017 Feb; 64(4):422-427. PubMed ID: 27927852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of Viremia in Postpartum Women on Antiretroviral Therapy.
    Hoffman RM; Warshaw MG; Amico KR; Pilotto J; Masheto G; Achalapong J; Machado E; Chokephaibulkit K; Duarte G; João E; Graham KK; Knapp KM; Stek AM; Scott GB; Coletti A; Loftis AJ; Chakhtoura N; Currier JS;
    J Acquir Immune Defic Syndr; 2020 Jan; 83(1):72-80. PubMed ID: 31651545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. It is safe to stop antiretroviral therapy in patients with preantiretroviral CD4 cell counts >250 cells/microL.
    Skiest DJ; Morrow P; Allen B; McKinsey J; Crosby C; Foster B; Hardy RD
    J Acquir Immune Defic Syndr; 2004 Nov; 37(3):1351-7. PubMed ID: 15483464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Continuation of postpartum antiretroviral therapy in a cohort of women infected with human immunodeficiency virus.
    Tedaldi E; Willard S; Gilmore J; Holdsworth C; Dix-Lassiter S; Axelrod P
    J Assoc Nurses AIDS Care; 2002; 13(1):60-5. PubMed ID: 11828860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Study on the prevalence of loss to follow-up and risk factors among human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) patients in Baoshan city, Yunnan province].
    Huang D; Zheng W; Yang J; Li Y; Hu A; Xu Z
    Zhonghua Yu Fang Yi Xue Za Zhi; 2014 Aug; 48(8):688-92. PubMed ID: 25388464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Revisiting Co-trimoxazole Prophylaxis for African Adults in the Era of Antiretroviral Therapy: A Randomized Controlled Clinical Trial.
    Laurens MB; Mungwira RG; Nampota N; Nyirenda OM; Divala TH; Kanjala M; Mkandawire FA; Galileya LT; Nyangulu W; Mwinjiwa E; Downs M; Tillman A; Taylor TE; Mallewa J; Plowe CV; van Oosterhout JJ; Laufer MK
    Clin Infect Dis; 2021 Sep; 73(6):1058-1065. PubMed ID: 33744963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brief Report: Long-Term Clinical, Immunologic, and Virologic Outcomes Among Early-Treated Children With HIV in Botswana: A Nonrandomized Controlled Clinical Trial.
    Ajibola G; Maswabi K; Hughes MD; Bennett K; Pretorius-Holme M; Capparelli EV; Jean-Philippe P; Moyo S; Mohammed T; Batlang O; Sakoi M; Ricci L; Lockman S; Makhema J; Kuritzkes DR; Lichterfeld M; Shapiro RL
    J Acquir Immune Defic Syndr; 2023 Apr; 92(5):393-398. PubMed ID: 36729692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of short term Antiretroviral Therapy (ART) interruptions on longer term maternal health outcomes-A randomized clinical trial.
    Atuhaire P; S Brummel S; Mmbaga BT; Angelidou K; Fairlie L; Violari A; Theron G; Mukuzunga C; Mawlana S; Mubiana-Mbewe M; Naidoo M; Makanani B; Mandima P; Nematadzira T; Suryavanshi N; Mbengeranwa T; Loftis A; Basar M; McCarthy K; Currier JS; Fowler MG;
    PLoS One; 2020; 15(1):e0228003. PubMed ID: 31999753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Morbidity and mortality according to latest CD4+ cell count among HIV positive individuals in South Africa who enrolled in project Phidisa.
    Maduna PH; Dolan M; Kondlo L; Mabuza H; Dlamini JN; Polis M; Mnisi T; Orsega S; Maja P; Ledwaba L; Molefe T; Sangweni P; Malan L; Matchaba G; Khabo P; Grandits G; Neaton JD
    PLoS One; 2015; 10(4):e0121843. PubMed ID: 25856495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.